Gap 26 is a connexin mimetic peptide, working as a Gap junction blocker. Gap26 inhibited electrical coupling in cell pairs mediated by gap junctions after exposure for 30 min, but inhibited hemichannel currents evoked in low Ca2+ solution with a response time of less than 5 min when applied to single cells. Gap 26 reduced the size of InsP3-triggered intercellular calcium waves at concentration of 0.25mg/ml post 30 minutes in RBE4 cells, blocked Photoliberating InsP3 triggered ATP release, but did not inhibit the gap junctional coupling between the cells.
作用机制
Gap 26 is a connexin mimetic peptide corresponding to short conserved extracellular loop sequences of connexins as reversible inhibitor of gap junctional intercellular communication.[1]
Gap 26 细胞实验
Cell Line
Concentration
Treated Time
Description
References
786-O cells
0.02 µg/µL and 0.04 µg/µL
12 hours
To evaluate the effect of Gap 26 on the migratory capacity of 786-O cells, results showed that the GAP26-treated group had an almost 2-fold increase in the rate of scratch healing compared to the control group
Medicina (Kaunas). 2024 May 8;60(5):780
astrocytes
100 μM
48 hours
Gap26 inhibited intercellular dye transfer and further inhibited cellular coupling.
Significantly inhibited γ-H2AX counts in the bystander zone but not in the irradiated zone
Cell Death Dis. 2020 Mar 18;11(3):194
RBE4 cells
161 μM
30 min pretreatment +3 h post irradiation
Significantly inhibited γ-H2AX-positive cell counts in both irradiated and bystander zones
Cell Death Dis. 2020 Mar 18;11(3):194
Human umbilical artery smooth muscle cells (HUASMCs)
0.25 mg/ml
Inhibited Cx43-GJs function, reduced Ca2+ transfer between neighboring cells, leading to significant decreases in F-actin polymerization and MLC2 phosphorylation
Cell Commun Signal. 2023 Jun 28;21(1):163
BEAS-2B cells
300 μM
1 hour
Inhibited Cx43 function and attenuated LPS-induced BEAS-2B cell damage
J Transl Med. 2016 Jun 30;14(1):194
white adipocytes
100 µM
30 minutes
completely suppressed Ca2+ oscillations in all white adipocytes
Int J Mol Sci. 2021 Jul 28;22(15):8095
Gap 26 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Male Wistar rats
Isolated perfused heart model
Perfusion buffer
0.5 µM
Prior to ischemia and initially during reperfusion
Gap26 significantly reduced infarct size to 72.9 ±5.8% of control infarcts. However, when combined with ischemic preconditioning (IPC), the protection was lost (109.6 ±8.0%).
Int J Mol Sci. 2022 Sep 5;23(17):10197
Male Wistar albino rats
CCl4-induced cirrhotic cardiomyopathy model
Intraperitoneal injection
1 µg/kg/day
Three times a week for eight weeks
To evaluate the effects of Gap 26 on cirrhotic cardiomyopathy. Results showed that Gap 26 improved myocardial responsiveness to isoproterenol, reduced QTc interval abnormalities, decreased spleen weight and oxidative stress markers MDA and ALT, and upregulated atrial Cx43 gene expression.
Tags:
Gap 26 | 197250-15-0 | Gap26 | Gap-26 | Gap Junction Inhibitor | Cytoskeleton | Gap Junction Protein | 仅供科研使用 | AmBeed-信号通路专用抑制剂
| Gap 26 纯度/质量文件
| Gap 26 生物活性
| Gap 26 动物研究
| Gap 26 参考文献
| Gap 26 实验方案
| Gap 26 技术信息
搜索
